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ABSTRACT 
Spontaneous bacterial peritonitis (SBP) is a frequent and severe complication in cirrhotic patients with ascites. To describe spontaneous 
bacterial peritonitis (SBP) in the context of currently accepted criteria for diagnosis, treatment and prevention. A review of SBP and its 
associated etiopathogenic factors is presented. Numerous studies on mechanisms of disease, bacteriology, epidemiology, diagnostic markers, 
and current guidelines for its diagnosis, treatment and prevention are discussed. Peritonitis in patients with ascites in the absence of 
secondary causes, such as perforation of a viscus, occurs primarily in patients with end-stage liver disease. Enteric organisms, mainly gram-
negative bacilli, probably translocate to regional lymph nodes to produce bacteremia and seeding of ascitic fluid. Signs and symptoms of 
peritonitis are usually subtle. The ascitic fluid polymorphonuclear leukocyte count is the best determinant for early diagnosis and treatment 
of SBP. Third-generation cephalosporins such as cefotaxime are considered the drugs of choice for treatment, whereas quinolones such as 
norfloxacin are used to decrease recurrence. Despite increased awareness, early diagnosis, and prompt and effective antimicrobial therapy, 
SBP recurs frequently and is associated with a high mortality rate. Patients with SBP should be assessed for candidacy for liver 
transplantation. 
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INTRODUCTION 
Bacterial infections are a well-known cause of morbidity and 
mortality in cirrhotic patients, being a leading aetiology of 
progression in liver failure1. Subjects suffering from liver 
cirrhosis can be considered as immunocompromised2 and as 
such, are more prone to infections, whose incidence and 
severity is greater than in non-cirrhotic individuals. 
Spontaneous bacterial peritonitis (SBP) and urinary tract 
infections are the most frequent infections in this setting3. 
Advanced liver disease is a concern in developed countries, 
representing the 14th most frequent cause of death globally 
and even the fourth in regions such central Europe4. One of 
the most important reasons of hepatic decompensation in 
cirrhotic patients is bacterial infections, which currently are 
deemed as a distinct prognostic stage of liver disease, 
worsening the outcome regardless of illness 
severity5.Unfortunately; in cirrhotic patients the diagnosis of 
bacterial infections is often very difficult. At any rate, they 
are the main inciting factor of the so-called acute-on-chronic 
liver failure, a clinical entity associated with organ failures 
and notable short-term mortality6. Spontaneous Bacterial 
Peritonitis had been reported earlier, SBP was first defined 
by Dr. Harold O. Connen in 1964 that identified it as an 
infection of the peritoneal fluid with no obvious source 
within the abdomen that is liable to surgical treatment7-9. 
SPB is diagnosed when a culture is positive for ascites and 
there is a high count of polymorphonuclear leukocytes 
(PMN). SBP is one of the most frequent and life-threatening 
complications of patients with cirrhosis. Mortality rates have 
stayed constant in spite of the development of new antibiotic 
treatments and early diagnosis of SBP infection10. In their 
study, Singh and colleagues described the mortality rate of 
SBP in two different cohorts over a ten-year period and did 
not find any difference between the cohorts11. The in-
hospital mortality rate can reach 30% in spite of infection 
control measures; mortality being generally due to 
complications such as acute variceal bleeding, development 
of thehepato-renal syndrome, or progressive liver 
failure10,12-16. The incidence of SBP has been estimated in 
10% to 30% of unselected patients admitted to 
hospital10,11,13,15-17  Nevertheless, recent studies tend to 
demonstrate that SBP incidence seems to be decreasing12. A 
recent multicenter study carried out in 70 different centers 
observed an incidence of SPB of 5.5%18. We studied 
prospectively 200 samples of ascitic fluid of 106 cirrhotic 
patients and detected SBP in 11% of the studied population 
in both inpatient and outpatient settings. In asymptomatic 
outpatients that were submitted to therapeutic paracenteses 
the incidence of SBP seems to be lower and is estimated at 
0.57% to 3.5%19,20.The outcome of SBP in this group of 
patient has been demonstrated to be better than in 
hospitalized cirrhotic patients. The probability of 
development of the first episode of SBP over a one-year 
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period in patients with end-stage-liver disease and ascites is 
around 10%.The mainstay of SBP physiopathology seems to 
be the association of bacterial translocation with the 
decrease in host immune system defenses. It has been 
demonstrated, firstly in animal models with ascites and later 
in cirrhotic patients, that passage of intestinal bacteria from 
the gut to extra intestinal sites could be increased21, 22. 
Studies using oral nonabsorbable antibiotics reinforce the 
hypothesis that exist a causal relationship between bacterial 
translocation and the occurrence of SBP. The use of these 
antibiotics decreases the development of SBP and other 
spontaneous infections in cirrhotic patients23-25.The 
disturbance in small intestinal motility and the presence of 
hypochlorydria has been demonstrated to occur in cirrhotic 
patients and seems to be responsible for the bacterial 
overgrowth commonly observed in these patients26. The 
actual role of intestinal overgrowth in the pathogenesis of 
SBP has not yet been settled. Chang and colleagues 
demonstrated that the prevalence of bacterial overgrowth 
was higher in patients with a history of SBP associated to 
disturbances in small intestinal motility27. On the other hand, 
Bauer and colleagues26 were not able to confirm this 
hypothesis in their investigation. These bacteria are 
translocated through the intestinal wall, which has its 
permeability altered by the portal hypertension; in 
consequence they reach the mesenteric lymphnodes. After 
that, they move to the systemic circulation until they contact 
the ascitic fluid. Other sites than gut have been demonstrated 
to originate bacteria seeding. These could be represented by 
pneumococcal sepsis, cellulites, urinary tract and dental 
infections19,  27. Once the bacteria reach the ascitic fluid, the 
host immune defense is responsible for the occurrence or 
not of SBP. The macrophages are the first line of defense of 
the peritoneal cavity and the impairment in phagocytic 
activity of reticulendothelial system (RES) can cause a 
prolonged bacteremia. The liver is the largest organ of the 
RES and this dysfunction evidently imposes infectious risks. 
The next step of immune system defense is the activation of 
complement with further release of cytokines. The 
polymorphonuclear neutrophilic leukocytes (PMNs) try to 
destroy the bacteria by entering in the peritoneal cavity. The 
dysfunction of PMNs and the low levels of complement, both 
by decreasing in liver production associated to increased 
consumption as an acute phase response, are commonly 
observed in cirrhosis and seem to contribute to the 
conversion of ascitic fluid colonization into SBP28-30. For such 
reasons cirrhosis is considered one of the most common 
current forms of acquired immune deficiency. More recently, 
Christou and colleagues31 indicated bacteremia/sepsis, 
respiratory and urinary tract infection, meningitis, 
endocarditis, phlegmonous colitis and hepatic abscess as 
other common specific infectious complications beyond SBP, 
in hepatic cirrhosis. Ascites is thought to arise as a result of 
the marked circulatory and renal abnormalities that are 
associated with cirrhosis32-34 and patients who develop this 
complication have a 2-year survival of approximately 50%35. 
The physiological changes leading to its formation have been 
encompassed in the peripheral vasodilatation hypothesis of 
Schrier et al36. This proposes that initial arterial 
vasodilatation leads to a reduced effective arterial blood 
volume and subsequent activation of mediators promoting 
sodium and water retention37.These include the rennin-
angiotensin-aldosterone system, the sympathetic nervous 
system and anti-diuretic hormone. In addition, the renal 
circulation appears particularly sensitive to angiotensin-II-
mediated vasoconstriction38 which may lead to reduced 
renal perfusion and glomerular altration rate. Thus patients 
with cirrhosis and ascites exhibit a precarious 
haemodynamic imbalance. If they are exposed to an 
additional insult, such as a gastrointestinal bleed, 
nephrotoxic drugs (e.g. NSAIDs, diuretics, aminoglycosides) 
or systemic infection, they are at risk of developing renal 
impairment and the hepatorenal syndrome. The aim of this 
systematic review is to provide a comprehensive overview of 
the microbiological features risk factors, ascitic fluid 
interpretation, pathogenesis, treatment, prophylaxis and 
evolving perspectives related to SBP. 
PATHOGENESIS 
Initially the term spontaneous was used because the cause of 
the infection was not clearly identifiable. Over time it has 
been partially clarified. Many factors contribute to the 
pathogenesis of SBP. One of them is bacterial translocation 
that consists of passage of bacteria from the intestinal lumen 
to mesenteric lymph nodes. This process is favored by three 
main factors: bacterial overgrowth, alteration of the 
intestinal mucosal and impaired local and systemic 
immunity. Bacterial overgrowth itself is favored by the 
impaired motility of the small intestine and functional 
changes in the intestinal mucosa are explained by increased 
permeability. The low concentration of hydrochloric acid 
produced by the use of proton pump inhibitors (PPIs) in 
cirrhotic patients is another factor. Some studies have found 
that patients who have cirrhosis and who are using PPIs 
have three times the risk of cirrhotic patients who do not use 
PPIs of developing SBP. Studies have shown that bacterial 
translocation increases in cirrhotic patients because of 
reduced local immunity that prevents bacterial clearance so 
that the bacteria is able to infect the mesenteric lymph nodes 
from where they can circulate systemically causing 
bacteremia. More frequent and longer lasting bacteremia 
occurs in cirrhotic patients because of their 
immunosuppressed states which are principally due to 
hypoalbuminemia and because of portosystemic shunts with 
alter the functioning of the mononuclear phagocyte system39. 
Intestinal bacterial overgrowth
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Figure 1: Pathogenesis of SBP40. 
BACTERIOLOGY  
In a healthy individual, the variety and density of bacteria 
increases exponentially from the stomach to the colon with 
up to a 1000 or more different species and a trillion bacteria 
per gram of faecal material in the caecum. A symbiotic 
relationship usually exists. However, in advanced liver 
disease, normal intestinal flora can cause deleterious effects 
to the host through a variety of mechanisms leading to SBP 
including bacterial overgrowth, increased intestinal 
permeability so-called leaky gut and pathological bacterial 
translocation-all in the setting of immune dysregulation 
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pervasive in patients with cirrhosis. Gram-negative bacilli 
are the major cause of SBP. The three most common isolates 
from 263 ascitic fluid cultures, compiled in 1994 from 
various studies published between 1971 and 1991, included 
E. coli (46%), Streptococcus (30%) and Klebsiella (9%). 
Similar results were demonstrated in 1992 from numerous 
studies encompassing 746 cases of SBP: E. coli (47%), 
Streptococcus (19%) and Klebsiella (13%). E. coli was found 
in the majority of patients with SBP as reported by Conn et 
al. (66%) 41 and Kerr et al. (72%) 42 And consistently remains 
most common isolate in recent literature albeit with lower 
prevalence. E. coli was the predominant strain to cause of 
SBP reported by Fernandez et al 43. From data obtained 
between 1998 and 2000 accounting for 34 of 138 cases 
(25%) of SBP. Likewise, E. coli represented 31 of 140 cases 
(22%) as reported by Novovic et al44 from data gathered 
between 2000 and 2006. Gram-positive cocci have generally 
accounted for less than 25% of cases of SBP. Infections with 
Gram-positive cocci including pneumonia and urinary tract 
infections have markedly increased in patients with cirrhosis 
in recent years and have been linked to therapeutic 
intervention and chronic antibiotic usage. The increasing 
trend of Gram-positive cocci-related SBP has also been 
demonstrated and represents a changing paradigm in the 
known bacteriology of SBP. Notably, 229 Gram-positive cocci 
were identified on ascitic fluid culture compared to 151 
Gram-negative bacilli out of 411 strains from 325 subjects. 
The most frequently encountered bacteria were coagulase-
negative staphylococci (n=85), E. coli (n = 75), enterococci 
(n=54), streptococci (n=50), Klebsiella (n=33), Enterobacter 
(n=33), Serratia (n = 33) and S. aureus (n=33). An 
observational French study from the same affiliate acquired 
268 positive culture results from patients with cirrhosis and 
Gram-positive cocci related SBP was the predominate group 
representing 65% (coagulase-negative Staphylococcus 27%, 
Enterococcus 24%) of SBP cases validating prior findings. 
The spectrum of bacteria causing SBP in inpatients from nine 
studies with ascitic fluid samples collected since 1998 has 
demonstrated comparable results in an original table herein. 
However, Gram-negative bacilli and foremost E. coli remain 
the most common class of bacteria and isolate respectively. 
The prevalence of SBP generally remains low in the out-
patient setting especially in asymptomatic patients. Culture 
results from 427 out-patients demonstrated 1% prevalence 
of SBP which was predominately Gram-positive cocci 
[Staphylococcus aureus (n=1), Streptococcus viridans (n=3) 
and Staphylococcus saccharolyticus (n=1). The emergence of 
extended spectrum b-lactamaseproducing (ESbL) Gram-
negative bacilli, methicillin-resistant Staphylococcus aureus 
(MRSA), flouroquinolone-resistant (QR) Gram-negative 
bacilli, vancomycin-resistant Enterococcus and other 
resistant microorganisms have also changed prior 
perceptions about SBP bacteriology and its treatment. MRSA 
was found to cause 9 of 87 SBP cases (10%) in a prospective 
study. In another study, the same research group found SBP 
was due to GPC in 34 of 60 cases (57%) when patients 
received norfloxacin for more than 1 month, and MRSA was 
the most common isolate (77%). Extended spectrum b-
lactamase-producing (ESbL) Gram-negative bacilli (E. coli 
and Klebsiella) were the most common multi-drug resistant 
bacteria (73%), especially among nosocomial infections, 
followed by fluoroquinolone resistant Gram-negative bacilli 
in patients who were receiving norfloxacin prophylaxis. One 
bacterium (monomicrobial) is the cause in more than 90% of 
cases, yet the probability of identifying a pathogen is 
mediocre as ascitic fluid cultures are positive in 50–60% of 
patients with SBP. Rare isolates reported in the literature 
include anaerobes, Aeromonas, Listeria, Streptococcus bovis, 
Bordetella bronchiseptica, Candida, Pasteurella multocida, 
Leclercia adecarboxylata and Salmonella paratyphi A45. 
EPIDEMEOLOGY  
SBP can occur in adults and children. In children, it most 
commonly occurs in neonates and those around five years of 
age. It is most common in patients with cirrhosis, though it 
can occur as a complication of any disease that results in 
accumulation of ascitic fluid, such as liver disease, Budd-
Chiari syndrome, congestive heart failure, systemic lupus 
erythematosus, renal failure, or cancers, and has a poor 
prognosis. Approximately 10% to 25% of patients with 
ascites will develop SBP, and the condition is associated with 
a 20% in-hospital rate of mortality. Patients with a prior 
incidence of SBP are more likely to encounter a subsequent 
infection with a drug-resistant organism. Additionally, the 
risk of developing SBP increases with age, use of proton-
pump inhibitors (PPIs), and when undergoing SBP 
prophylaxis such as selective intestinal decontamination46.  
DIAGNOSTIC MARKERS OF SBP 
The gold standard for a diagnosis of SBP is the PMN count in 
the ascetic fluid, but paracentesis is not always possible. 
Laboratory markers are useful for early diagnosis of SBP and 
early prediction of the response to initial treatment because 
a lack of response is a predictor of SBP mortality. TNF-α and 
interleukin-6 are significantly higher in the ascitic fluid of 
patients with SBP than in those with sterile ascites and 
increases of those proinflammatory cytokines have been 
associated with renal impairment complicated by SBP and 
with mortality. The lactoferrin concentration is also higher in 
patients with SBP than in those with sterile ascites and the 
lactoferrin level in ascitic fluid has shown high sensitivity 
and specificity for the diagnosis of SBP. The optimal timing of 
lactoferrin assays is not yet clear and diagnostic assay kits 
are not commercially available Procalcitonin, a prohormone 
of calcitonin synthesized in the C cells of the thyroid gland, is 
an acute-phase reactant protein that has been studied in 
patients with SBP. Seven studies assayed serum 
procalcitonin; three assayed procalcitonin in ascitic fluid. 
Serum procalcitonin was significantly higher in SBP than in 
sterile ascites in six of the seven which supports use of 
serum procalcitonin as an SBP marker. In a review by Yang 
et al47 of the available data from 339 patients with LC 
accompanied by SBP, it was concluded that serum 
procalcitonin was a relatively sensitive and specific marker 
for the diagnosis of SBP. It has been reported that serum 
procalcitonin was significantly higher in cirrhotic patients 
with culture-positive SBP than in those with CNNA. Two of 
the three evaluations of procalcitonin in ascitic fluid found 
no significant differences in procalcitonin levels in patients 
with SBP and those with sterile ascites. The usefulness of 
ascitic fluid procalcitonin to distinguish between SBP and 
sterile ascites has not been demonstrated. Calprotectin is a 
calcium- and zinc-binding protein with antimicrobial and 
antiproliferative functions. It is almost exclusively expressed 
in neutrophils and its level in body fluids is proportional to 
the influx of neutrophils. Burri et al48 reported that ascitic 
fluid calprotectin level was correlated with the PMN count 
and that it reliably predicted a count of ≥ 250 cells/mm3, 
which is the standard for a diagnosis of SBP. Subsequent 
studies found that ascites calprotectin is significantly higher 
in cirrhotic patients with SBP than in those without SBP. Lutz 
et al49 have shown that the ratio of calprotectin to total 
protein in ascitic fluid was a better diagnostic marker of SBP 
than calprotectin alone and that a high ratio was 
independently associated with 30-d mortality Leukocyte 
esterase activity, which can be assayed with commercially 
available reagent strips, may have diagnostic value. 
Chouhan et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2018; 8(6-s):384-393  
ISSN: 2250-1177                                                                                 [387]                                                                                  CODEN (USA): JDDTAO 
Castellote et al50 reported that the use of reagent strips is a 
rapid and inexpensive tool for the diagnosis of ascitic fluid 
infection and it had a high negative predictive value (99%), 
indicating that a negative result may be useful as screening 
to exclude SBP. Oey et al51 reviewed 23 studies of leukocyte 
esterase in patients with SBP published between 2002 and 
2015 and concluded that it had poor sensitivity and positive 
predictive value for the diagnosis of SBP. They found that the 
sensitivity of the reagent strips for diagnosing SBP was 
variable, and a negative test result strongly suggested the 
absence of SBP. In another review of 26 studies published 
from 2002 to 2010, Koulaouzidis52 confirmed the poor 
sensitivity and poor positive predictive value of leukocyte 
esterase activity as well as the high 93%-100% negative 
predictive value. A negative test result may thus indicate a 
high probability of the absence of SBP. There is evidence for 
the diagnostic value of other markers including monocyte 
chemotactic protein-1 in serum  and ascitic fluid, 
lipopolysaccharide-binding protein in serum and ascitic 
fluid, macrophage inflammatory protein type-1 beta in 
ascitic fluid, interferon-γ-induced protein-10 in serum and 
ascitic fluid, triggering receptor expressed on myeloid cells-1 
in ascitic fluid, high-sensitivity CRP in serum and ascitic fluid  
and neutrophil gelatinase-associated lipocalin in ascitic fluid. 
Further study is needed to validate the diagnostic usefulness 
of these candidate markers53. 
The possible serum or ascitic fluid markers of spontaneous 
bacterial peritonitis reported in previous studies54. Are as 
follows: Serum- Tumor necrosis factor-α, Interleukin-6, 
Procalcitonin, Interferon-induced protein 10 kDa, High-
sensitivity CRP, Ascitic fluid-Tumor necrosis factor-α, 
Interleukin-6, Lactoferrin, Calprotectin, Leukocyte esterase 
reagent strips, Macrophage inflammatory protein type 1 β, 
Interferon-γ-induced protein 10 kDa, Triggering receptor 
expressed on myeloid cells 1, High-sensitivity CRP. 
HISTORY AND PHYSICAL 
One should have a high index of suspicion for SBP in all 
patients presenting with ascites, and this is especially true if 
the patient has an acute history of clinical deterioration. The 
majority of patients with SBP will present with fever, chills, 
nausea, vomiting and abdominal pain, although some 
patients may be asymptomatic and SBP is an incidental 
finding. Fever is the most common symptom encountered in 
patients with SBP, which is a particularly useful clinical 
symptom as patients with cirrhosis are typically 
hypothermic. Additional signs and symptoms include 
diarrhea, paralytic ileus, new-onset or worsening 
encephalopathy (e.g., altered mental status) without any 
other identifiable cause, new-onset or worsening renal 
failure, or presence of ascites that does not improve with use 
of diuretic medications. On physical examination, most 
patients will have a tender abdomen, although patient 
response can vary from mild discomfort to the presence of 
guarding and rebound tenderness. In cases of acute or 
chronic liver failure SBP is one of the main triggers for 
hepatic encephalopathy, and where there is no other clear 
causal indication for this, SBP may be suspected. These 
symptoms can also be the same for a spontaneous fungal 
peritonitis (SFP) and therefore make a differentiation 
difficult. Delay of diagnosis can delay antifungal treatment 
and lead to a higher mortality rate54-56. 
DIAGNOSIS OF SBP 
Diagnostic paracentesis 
Paracentesis is extremely important, as the PMN count in the 
ascitic fluid plays an essential role in obtaining a diagnosis of 
SBP. Diagnostic paracentesis should be performed in all 
patients who present with  
(1) Compatible signs or symptoms.  
(2) Impairment of the hepatic or renal function 
(3) Unexplained hepatic encephalopathy 
(4) Gastrointestinal bleeding. 
Although all cirrhotic patients with ascites are at risk of SBP, 
the prevalence of SBP among hospitalized patients (10%) is 
higher than that observed in outpatients (1.5–3.5%). It is 
therefore recommended that diagnostic paracentesis be 
performed in all cirrhotic patients with ascites who require 
hospital admission, regardless of whether they exhibit 
clinical symptom(s) of SBP. 
Ascitic fluid cell analysis 
Despite the use of a sensitive method ascites cultures often 
show negative results, even in patients with an increased 
ascitic PMN count and clinical symptoms suggestive of SBP. 
Therefore, the diagnosis of SBP is confirmed based on a PMN 
count in the ascites of >250 cells/mm3 in the absence of an 
intra-abdominal and surgically treatable source of infection. 
The cutoff value of 250 PMN cells/mm3 has the greatest 
sensitivity, whereas 500 PMN cells/mm3 exhibits the 
greatest specificity. However, the most sensitive cutoff value 
should be used for diagnosis, as it is important not to miss 
cases of SBP. Physicians should subtract one PMN for every 
250 red blood cells in patients with hemorrhagic ascites with 
a fluid red blood cell count of >10,000/mm3 (due to the 
effects of concomitant malignancy or traumatic tap) in order 
to adjust for the presence of blood in the ascites. The PMN 
count in the ascitic fluid may be determined according to a 
hematological method using either a light microscope and 
manual counting chamber or an automated cell counter. The 
ascitic fluid is centrifuged in order to manual count the 
number of ascitic cells, after which a smear of the collected 
cells is stained with Giemsa and the total and differential cell 
counts are determined using a light microscope. The 
microscopic cell counting method requires several hours and 
carries a risk at inter- and/or intra observer discrepancy. On 
the other hand, automated cell counters provide 
reproducible results within a few minutes; however, coulter 
counter findings of the neutrophil count have been shown to 
be inaccurate for relatively low levels of neutrophils in the 
ascitic fluid. Therefore, the manual PMN counting method is 
conventionally preferred. However, a recent study 
demonstrated that automated cell counts have sufficient 
sensitivity for diagnosing SBP, thus suggesting that this 
simple method may be used in place of traditional manual 
counting. 
Ascitic fluid culture  
Conventional bacterial culture methods, such as laboratory 
analyses of fluid collected in syringes or tubes, effectively 
detect bacteria in less than 50% of ascites samples with an 
elevated PMN count (>250/mm3). Therefore, it is 
recommended to inoculate the ascitic fluid into blood culture 
bottles at the patient’s bedside in order to increase the 
sensitivity of the bacterial culture. The culture-positive rate 
of SBP ascites is approximately 80%, namely, between 72% 
and 90% of cases assessed using the culture-bottle method. 
However, several recent studies have reported lower 
culture-positive rates for SBP ascites, ranging from 
approximately 40% to 60%. In addition, even with the 
sensitive culture-bottle method, positive results for ascitic 
cultures are estimated to be approximately 40–70%, 
according to various recent guidelines57-60. Since patients 
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with an increased PMN count in the ascitic fluid (>250 
cells/mm3) and negative cultures exhibit a clinical 
presentation similar to that of bacteriologically confirmed 
SBP, these patients are categorized as having culture 
negative SBP and should be treated in the same manner as 
those with culture-positive SBP.  
DIFFERENTIATION FROM SECONDARY BACTERIAL 
PERITONITIS 
Differentiating SBP from secondary peritonitis due to 
perforation or inflammation of intra-abdominal organs is 
clinically very important. Secondary bacterial peritonitis 
should be suspected in patients with relevant abdominal 
signs or symptoms, multiple organisms in ascitic cultures 
and a very high PMN count and/or high protein 
concentration in the ascites, as well as those who display an 
inadequate response to therapy. However, accurately 
diagnosing secondary peritonitis based on these criteria 
generally takes a long time and patients with perforated 
secondary peritonitis require surgical treatment in a timely 
fashion. Therefore, performing abdominal CT to detect 
perforation is recommended in patients with suspected 
secondary bacterial peritonitis. Various parameters available 
at the time of paracentesis have been proposed to assist in 
rapidly detecting secondary peritonitis. Parameters in the 
ascitic fluid in patients with secondary peritonitis, as 
proposed by Runyon and Hoefs61, are as follows:  
(1) An elevated PMN count in the ascitic fluid (>250/mm3: 
usually many thousands)  
(2) at least two of the following: a total protein level of >1 
g/dL, a serum lactate dehydrogenase level above the upper 
limit of normal and a glucose level of 240 U/l and 
carcinoembryonic antigen level of >5 ng/mL in the ascitic 
fluid have been reported to exhibit good diagnostic 
performance for detecting gut perforation into the ascitic 
fluid with a sensitivity of 92% and specificity of 88%. 
However, it is not easy to differentiate SBP from secondary 
peritonitis based only on biochemical parameters of ascitic 
samples, and abdominal CT is essential in the clinical 
setting72. 
POTENTIAL DIAGNOSTIC METHODS FOR SBP 
Leukocyte esterase reagent strips (LERS) 
 It takes several hours to obtain the results of an ascitic fluid 
cell count. Therefore, the use of leukocyte reagent strips has 
been proposed as a fast and inexpensive method for 
diagnosing SBP. These reagent strips, which were originally 
developed to diagnose urinary tract infections, detect 
leukocytes based on their esterase activity according to a 
colorimetric method. However, a large, multicenter 
prospective study recently showed that the Multistix 8 SG 
has a low level of diagnostic accuracy for diagnosing SBP, 
with a high false-negative rate (55%). In addition, a systemic 
review of 19 studies of several strips (including Multistix, 
Aution, Combur, Nephur, and UriScan) demonstrated that 
these LERS have both low sensitivity and a high risk of false-
negative results 62. According to a recent review of 26 studies 
regarding the validity of LERS for SBP diagnosis63, LERS 
display low sensitivity for diagnosing SBP, with significant 
interstudy variability among brands of LERS. However, LERS 
have consistently shown high negative predictive value 
(>95% in the majority of studies) and may therefore be used 
as a preliminary screening tool to diagnose SBP. However, 
the utility of LERS for diagnosing SBP has not been 
confirmed. Most of the above strips were developed for use 
in urine with a threshold of >50 PMN cells/mm3 ; however, 
the diagnostic performance of a reagent strip test calibrated 
for ascitic fluid with a cutoff of 250 PMN cells/mm3 has 
recently been reported 64. That study showed excellent 
results, with a sensitivity of 100% and a negative predictive 
value of 100%. Although these conclusions have yet to be 
confirmed in large multicenter trials, this method may 
provide a new and useful diagnostic tool for detecting SBP72. 
Measurement of leukocyte-derived proteins 
The levels of proteins, such as granulocyte elastase and 
lactoferrin , released by activated PMNs are elevated in 
patients with SBP. Lactoferrin shows notable sensitivity 
(95.5%) and specificity (97%) for diagnosing SBP, with a 
cutoff value of 242 ng/ml. Nevertheless, the diagnostic 
performance of this parameter must be further evaluated in 
other studies with a larger number of patients due to the 
small number of SBP cases in that study. In addition to the 
proteins described above, the levels of several inflammatory 
cytokines and chemokines in the ascitic fluid are reported to 
be associated with the severity of SBP. However, these 
potential diagnostic biomarkers are generated by host 
reactions against inflammatory stimulation and fail to 
provide any direct evidence of bacterial infection in SBP 
ascites72. 
Detection of bacterial DNA using polymerase chain 
reaction (PCR) 
Bacterial cultures require several days to obtain results. 
Hence, bacterial DNA detection and sequencing is 
increasingly being used to diagnose various infectious 
diseases. Some PCR-based methods for detecting bacterial 
DNA have also been applied to the microbiological diagnosis 
of SBP. However, these methods have received several major 
criticisms regarding the detection of bacterial DNA. First, 
most previous studies enrolled a limited number of patients 
and a recent report including a large number of patients 
showed poor results for diagnosis. Furthermore, previous 
studies have revealed serious concerns regarding 
contamination of bacterial DNA in the PCR system. 
Commercially available Taq-polymerases may be 
contaminated with bacterial DNA65,66. Moreover, the 
reagents used for DNA extraction procedures carry a risk of 
exposing the clinical samples to exogenous bacterial 
DNA67,68. Although PCR is a very sensitive method for 
detecting DNA, PCR-based methods display discrepant and 
controversial findings with respect to diagnostic 
performance in detecting the causative pathogen(s) in SBP 
patients with ascites, perhaps, or at least in part, due to the 
problems described above. Therefore, no definitive PCR 
based method for providing an accurate diagnosis of SBP has 
been established72. 
Bacterial DNA in SBP ascites using in situ hybridization  
A new strategy using an ISH method for detecting the 
genomic DNA of bacteria phagocytized in neutrophils and 
macrophages was recently developed to identify causal 
bacteria in cases of sepsis69-71. The utility of this ISH method 
for detecting bacterial genomic DNA phagocytized in the 
leukocytes of patients with sepsis has been demonstrated, 
providing evidence for the presence of bacterial infection in 
such cases. Notably, the ISH method is almost four times 
more sensitive than blood cultures in detecting the causal 
bacteria of sepsis70. In addition, the results of ISH tests can 
be acquired within one day, whereas it takes several days, at 
least, to obtain the results of cultures. Based on the rapid and 
sensitive detection of bacterial DNA provided by the ISH 
method, we investigated whether this method can be used to 
obtain direct evidence of bacterial infection in SBP patients 
with ascites.  In addition to the low amount of bacteria 
present in the ascitic fluid of SBP patients, phagocytosis and 
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the digestion of bacteria by leukocytes may reduce the 
amount of proliferative, suspended bacteria in the ascitic 
fluid, thus making it difficult to identify the pathogen using 
standard methods. Phagocytosis is thought be responsible 
for the low rate of detectable causative bacteria. Therefore, 
we attempted to detect ingested bacterial DNA using the ISH 
method. Since all bacteria have the 23S ribosomal RNA gene, 
a novel cDNA probe for this gene was generated to detect the 
genomic DNA of the causative bacteria72. 
RISK FACTORS 
Biochemical risk factors 
Well-established risk factors for developing an initial 
episode of SBP are low ascitic fluid protein level (<1 g/dL), 
elevated serum bilirubin level and advanced cirrhosis. The 
probability of developing an initial episode of SBP was 
substantially higher (24%) in patients with a low ascitic 
protein level (<1 g/dL) compared to higher levels (4%) at 3 
year follow-up of 127 patients. Low levels of 25-hydroxy 
vitamin D have been associated with mortality in patients 
with cirrhosis and development of SBP independent of 
Child–Pugh score. Risk factors for recurrence, based on 
univariate analysis are serum bilirubin (>4 mg/dL), 
prothrombin (≤45%) and low ascitic fluid protein 
concentration (<1 g/dL). Likewise, after evaluating 86 
patients who survived a first episode of SBP, a serum 
albumin level less than 2.85 g/dl at hospital discharge was 
strongly associated with SBP recurrence. 
Clinical risk factors 
Variceal haemorrhage predisposes to SBP and randomised 
trials have shown reduction in infection and mortality when 
antibiotics are administered upon admis-sion, now a 
standard of care in all patients with cir-rhosis and 
gastrointestinal bleeding whether or not ascites is present. 
Genetic risk factors 
The Toll-like receptor 2 (TLR2) proteins are expressed in 
macrophages and are essential for recognition of microbial 
components and host cell defence. One hun-dred and fifty 
patients with cirrhosis and ascites were genotyped for TLR2, 
and those with specific TLR2 variants had a significant risk 
of developing SBP (38.5% vs. 15.3%, P = 0.002). Similarly, 
variants of the NOD2 (nucleotide-binding oligomerisation 
domain containing gene were initially found to impair 
mucosal integrity in Crohn disease in earlier studies and 
have also shown to increase the risk of SBP [P = 0.008, odds 
ratio (OR) = 3.06] and early death (P = 0.007) compared to 
wildtype genotypes in patients with cirrhosis and asci-tes.84 
Farnesoid X is a cellular protein and nuclear recep-tor and its 
polymorphisms have also been associated with risk of SBP in 
cirrhotic patients with ascites. 
PHARMACOLOGICAL RISK FACTORS 
Acid suppressive therapy 
 Proton pumps inhibitors (PPI) increase gastric pH, impair 
natural host defence against ingested bacteria and 
predispose to an altered intestinal milieu. PPIs have been 
associated with pneumonia and implicated in other 
infections such as SBP. In fact, PPI therapy has been 
associated with and identified as an independent risk factor 
for SBP in patients with advanced cirrhosis in retrospective 
series as well as prospective series, and its use should be 
curtailed or at least re-examined in this population as 50% of 
patients who develop SBP have no documented indication 
for PPI therapy.  In a meta-analysis, PPI therapy was found to 
increase the risk of SBP by three-fold in hospitalised patients 
with cirrhosis compared to those not receiving acid 
suppressive medication. In another meta-analysis including 
four studies with 772 patients, there was a sig-nificant 
association between PPI use and SBP (OR 2.77, 95% CI 1.82–
4.23). Moreover, in a large multi-centre prospective study 
examining 188 hospitalised patients with cirrhosis and 
infections, PPI therapy imposed the highest risk for re-
infection including SBP (OR 2.94, 95% CI, 1.39–6.20) within 
6 months. Cause and effect of PPI-related SBP has not been 
proven. However, PPI therapy and its association with other 
infections is widely familiar and applying these concepts is at 
the discretion of the clinician on a case-by-case basis until 
there is sur-mounting evidence to restrict its use in patients 
with ascites. 
Beta-adrenergic antagonist therapy 
 Beta-adrenergic antagonists namely nonselective beta-
blocker (NSBB) therapy was found to be protective for SBP 
as reported in a meta-analysis examining three retrospective 
and three randomised controlled trials, which demonstrated 
a statistically significant difference (12.1%, P < 0.001) in 
favour of propranolol for SBP prevention in patients with 
predominantly child class A and B cirrhosis. However, 
evidence and expert opinion herald caution with NSBB use in 
patients with end-stage liver disease and discontinuation of 
such therapy in the setting of refractory ascites due to poor 
cardiac compensatory reserve in these patients. Survival was 
significantly decreased in patients with cirrhosis and 
refractory ascites who were receiving NSBBs as opposed to 
patients not receiving NSBBs who lived nearly 2 years 
longer. NSBB therapy also reduced transplant-free survival 
in patients with cirrhosis after a first episode of SBP and 
conferred greater risk for complications requiring 
hospitalisation such as haemodynamic instability and renal 
insufficiency. 
Liver transplantation 
Spontaneous bacterial peritonitis is not a contraindication 
for liver transplantation, rather it should be considered after 
a first episode of SBP or sooner unless predisposing factors 
make patients unsuitable candidates. A 5-day course of 
antibiotics is adequate to effectively treat patients with SBP 
who undergo liver transplantation in the acute period. Post-
treatment paracentesis is prudent to ensure pathogen 
eradication. Furthermore, patients with or without a history 
of SBP have similar 4-year outcomes after liver 
transplantation including morbidity and mortality45. 
TREATMENT 
Intravenous antibiotics 
If suspicion for SBP arises then antibiotics should be started 
immediately to reduce complications and improve survival. 
Third-generation, broad-spectrum cephalosporins are the 
agents of choice for SBP treatment because of their 
superiority in randomised controlled trials and rare side 
effect profile with minimal risk of nephrotoxicity compared 
to other antibiotics. Cefotaxime covers most culprit 
pathogens, has excellent ascitic fluid penetration and 
achieves sterilisation in 94% of cases after initial antibiotic 
dosing. Treatment efficacy and clinical resolution with 
cefotaxime 4 g/day has ranged from 77% to 98%. Higher 
dosing, i.e. 8 g/day has not provided a therapeutic advantage. 
However, cefotaxime 2 g every 8 h (6 g/day) is considered 
the standard regimen and current guideline 
recommendation put forth by the American Association for 
the Study of Liver Diseases73. A 5-day course of cefotaxime 2 
g every 8 h is as effective as 10 days of treatment. No 
differences were seen with infection cure, SBP recurrence 
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and hospital mortality rates. Alternative intravenous 
antibiotic regimens for SBP include amoxicillin–clavulanic 
acid, which has comparable results to cefotaxime, ampicillin 
and gentamicin, and fluoroquinolones. Antibiotics other than 
third-generation cephalosporins have an increased risk for 
adverse events and there is less evidence supporting their 
role in primary treatment. A second-line choice of third-
generation cephalosporins is ceftriaxone, a strongly protein 
bound antibiotic and because of poor protein synthesis in 
cirrhotic patients is theoretically less effective for SBP 
treatment. Nevertheless, ceftriaxone has been well studied 
for primary treatment of SBP and although considered 
inferior to cefotaxime, ceftriaxone is effective therapy 
particularly at doses of 2 g/day for 5 days.  Aminoglycosides 
cause renal impairment in 5% of patients and should be 
avoided in patients with cirrhosis who have considerable 
risk for renal injury.  Fluoroquinolones have comparable 
ascitic fluid penetration to cephalosporins. Levofloxacin has 
shown similar efficacy compared to (cefotaxime and 
cefepime) at providing E. coli coverage [71% vs. (82%)] and 
coagulasenegative Staphylococcus coverage [90% vs. (44%)] 
in patients with SBP not receiving fluoroquinolone 
prophylaxis. In patients with penicillin allergy who are not 
receiving long-term fluoroquinolone therapy, levofloxacin is 
a reasonable and safe alternative treatment for SBP45. 
Oral antibiotics  
Oral fluoroquinolones are generally acceptable for 
uncomplicated SBP. Fluoroquinolones have excellent oral 
bioavailability ranging from 70% for ciprofloxacin to 95% 
for levofloxacin. In a randomised controlled trial, oral 
ofloxacin and IV cefotaxime resolved SBP at the same rate 
(84% vs. 85%) respectively74. 
Switch therapy 
In a randomised study in 2000 Terg et al75 showed that 
patients with SBP can be adequately treated with oral 
ciprofloxacin after a short course of IV ciprofloxacin. Switch 
therapy with oral ciprofloxacin was as effective as IV 
ciprofloxacin at infection resolution in a randomised study 
involving patients with SBP and was more cost effective. 
Antibiotics for multi-resistant bacteria  
Emergence of antibiotic resistance and changing profile to 
SBP-causing-bacteria has made standard treatment less 
reliable in some instances. In fact, 8–22% of 
Enterobacteriaceae have cephalosporin resistance. A 5-year 
retrospective study of 67 patients with SBP revealed that 
long-term prophylactic norfloxacin treatment reduced the 
risk of Gram-negative infections but increased the risk of 
severe hospital-acquired staphylococcal infections, whereby 
77% were methicillin-resistant76. 
Albumin 
Albumin is a single chain peptide protein, made in the liver, 
with a half-life of approximately 21 days. It regulates plasma 
oncotic pressure, buffers plasma, scavenges free radicals and 
transports hormones, fatty acids, unconjugated bilirubin, 
metals, ions and drugs. The structure and function of 
albumin is abnormal in advanced liver disease thereby 
impairing many key physiological processes. 
Hypoalbuminemia has myriad causes and is associated with 
increased morbidity and mortality regardless of aetiology. 
Albumin is cornerstone therapy for select patients with SBP 
in addition to antibiotics. A randomised, controlled trial 
involving patients with SBP treated with cefotaxime alone 
compared to cefotaxime and albumin (1.5 g/kg within 6 h of 
diagnosis, followed by 1 g/kg on day 3) demonstrated that 
by adding albumin patients avoided irreversible renal 
impairment (10 vs. 33%, P = 0.002) and had lower mortality 
both during hospitalisation (10 vs. 29%, P = 0.01) and at 3-
month follow-up after discharge (22 vs. 41%, P = 0.03). 
Renal impairment occurs in one-third of patients with SBP 
and albumin is not indicated for all patients. Patients should 
be carefully screened to receive albumin infusion, because 
those at risk for renal impairment have clearly shown 
benefit.  Patients with chronic kidney disease with or 
without dialysis dependency that develops SBP should 
receive albumin therapy77,78.  
PREVENTION  
Primary prophylaxis  
Norfloxacin 
Spontaneous bacterial peritonitis native patients with 
cirrhosis and low ascitic fluid protein (<1 g/dl) with 
additional risk factors are candidates to receive long-term 
norfloxacin therapy for survival benefit and to reduce risk of 
SBP as well as extraperitoneal infections. Norfloxacin has 
been the most widely studied antibiotic for SBP prevention 
in a variety of settings including gastrointestinal bleeding, 
primary SBP prophylaxis and secondary SBP prophylaxis 
and remains the first-line choice for selective intestinal 
decontamination.  
Ciprofloxacin 
The risk of developing an initial episode of community 
acquired SBP within 1 year is substantially higher (55%) in 
patients with low ascitic fluid protein (≤1 g/dl) and a 
bilirubin level greater than 3.2 mg/ dl and/or platelet count 
less than 98 000/mm3 compared to patients without these 
bilirubin and platelet cut-offs whose risk is approximately 
24%. There is one randomised, placebo-controlled trial that 
examined the role of ciprofloxacin in primary prophylaxis 
and found that patients with ascitic protein <1.5 g/dl who 
were receiving oral ciprofloxacin 500 mg/day had a 
significantly greater chance of survival in 1 year than 
patients receiving placebo (86% vs. 66%, P < 0.04) 45. 
Trimethoprim–sulfamethoxazole 
 A randomised controlled trial involving 66 consecutive 
patients with cirrhosis and ascites at a University-affiliated 
VA medical centre demonstrated decreased risk of SBP (27% 
vs. 3%, P = 0.025) and other infections with daily double 
strength trimethoprim–sulfamethoxazole at 90-day follow-
up79. 
Rifaximin 
There is limited and inconsistent data for rifaximin a non-
absorbable antibiotic with broad-spectrum coverage, in 
primary or secondary SBP prophylaxis80. 
Secondary prophylaxis 
Norfloxacin 
Patients with a prior history of SBP are also candidates to 
receive indefinite antibiotic prophylaxis that is until liver 
transplantation, resolution of ascites or death. Recurrence of 
SBP ranges from 43% at 6 months to 74% at 2 years after 
initial diagnosis. 
Ciprofloxacin 
A meta-analysis reported short-term survival and reduced 
overall risk of infections with antibiotic prophylaxis when 
compared to untreated control groups. 
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Trimethoprim–sulfamethoxazole 
Trimethoprim–sulfamethoxazole demonstrated similar 
efficacy and adverse effect profile compared to norfloxacin 
for prevention of SBP recurrence in a retrospective series. 
Trimethoprim– sulfamethoxazole and norfloxacin for 
primary and secondary SBP prophylaxis also demonstrated 
similar and significant cost savings per patient per year. 
SUPPORTIVE THERAPY 
Diet 
Patients with advanced cirrhosis have continued protein 
catabolism, also referred to as hypermetabolism  and the 
majority suffer from malnutrition. There are no studies 
assessing the role of diet in prevention or treatment of SBP; 
however, malnutrition predisposes to bacterial translocation 
and SBP as demonstrated in experiments with rats. Simple 
evidence-based dietary measures should not be overlooked 
when providing patient recommendations. Referral for 
dietician consultation is at the discretion of clinicians and 
will at least imprint the importance of diet in health. Patients 
with cirrhosis should avoid raw food due to the risk of 
consuming harmful bacteria, limit dietary sodium intake, aim 
for 1.2–1.5 g of daily protein intake and generally should 
consume 4–6 small frequent meals throughout the day 
including a bedtime carbohydrate-rich snack45. 
Probiotics 
Anaerobic bacteria species such as Lactobacillus and Bifi-
dobacterium are normal inhabitants of the gastrointestinal 
lumen are less likely to translocate compared to Gram-
negative aerobic bacteria and have been hypothesised to 
play a role in the prevention of SBP. In fact, VSL#3 
(Lactobacillus spp., Bifidobacterium spp., Streptococcus 
salivarius spp. and Thermophilus spp.) has been shown to 
improve hepatic function and decrease liver enzymes in 
patients with cirrhosis and Lactobacillus combined with 
antioxidants (vitamin C and glutamate) have been shown to 
decrease endotoxemia compared to water lavage in rats with 
induced cirrhosis. Subsequent studies involving a similar rat 
model have used Lactobacillus alone which has succeeded in 
changing the intestinal milieu of the host but not SBP 
occurrence. The addition of probiotics to a daily norfloxacin 
regimen did not improve outcomes with regard to primary 
or secondary SBP prophylaxis nor did it demonstrate a 
survival benefit in a randomised, double-blind, placebo-
controlled trial with 6-month followup. The health benefits 
of probiotic therapy for a variety of gastrointestinal illnesses 
are well known although no evidence supports their use in 
the prevention or management of SBP45. 
FUTURE PERSPECTIVES 
Host response-based serum biomarkers such as 
procalcitonin (PCT) and c-reactive protein are the most 
frequently used serum markers for the early detection (as 
well as to test the severity) of bacterial infection, to 
complement direct pathogen detection. Unfortunately, their 
sensitivity and specificity in cirrhotic patients is impaired by 
a wide array of factors, among them the stimulus 
represented by the bacterial translocation through the gut, 
which, irrespective of real infection, stands out. Recently, 
new markers have been proposed for the early diagnosis of 
peritonitis, including lactoferrin, expression of CD64 on 
neutrophils (CD64 index), serum PCT and ascitic 
calprotectin. Lactoferrin may be useful to diagnose SBP in 
ESLD patients; the limit of this method is that elevated ascitic 
fluid lactoferrin level may also be related to hepatocellular 
carcinoma in ESLD patients without SBP. Another potential 
marker of SBP in cirrhotic patients is the CD64 index and this 
could be used as a more effective marker of PMN counts to 
modulate antimicrobial therapy.The aforementioned PCT is a 
valid test to diagnose SBP but as shown by a recent meta-
analysis, it cannot serve as a standalone examination and 
needs further clinical or laboratory findings. Ascitic 
calprotectin is an accurate marker for SP especially when it 
is combined with serum procalcitonin and the combined use 
of these two markers is very promising. Notwithstanding, 
these tools present an important limitation: they do not 
permit the etiological diagnosis of SP. On the other hand, 
methods able to detect a few bacteria per milliliter might 
potentially serve as a game-changer in the microbiological 
field: for instance, label-free bimodal waveguide 
immunosensor demonstrates this property and in the future 
could possibly become a very user-friendly tool for clinical 
microbiologists. Meanwhile, the objective of rapid diagnostic 
platforms is to provide a (near) point-of-care system to yield 
microbiological results within 1–2 hours: potential pitfalls 
could be the clinical significance of detected bacteria in the 
context of massive gut bacterial translocation (when no clear 
signs and/or symptoms of infection are present) and the 
limited number of the pathogens identified by the panels.The 
20th century has been characterized by the dramatic effect 
of the large-scale use of antibiotics after their discovery, 
saving millions of lives. Unfortunately, natural selection and 
misuse of antibiotics, both in human beings and in animals, 
have led to the development of difficult to treat infections by 
multi-drug resistant bacteria, also known as superbugs, the 
nightmare of the new century. Research efforts by 
pharmaceutical companies are not keeping pace with the 
worldwide spread of superbugs and this has prompted new 
strategies to optimize existing resources, such as the reviving 
of old antibiotics, the implementation of antimicrobial 
stewardship programs and the judicious use of new anti-
infective agents. However, the epidemiology of bacterial 
infections has a huge intercentre variability and the 
therapeutic approach should be inspired by the principle of 
one size does not fit all which obviously also applies to SBP. 
In other words, the current challenge is to accurately identify 
patients with SBP for whom empirical broad-spectrum 
therapy would be appropriate, with special attention to 
MDR-GPB in contexts where their prevalence is relevant. 
Risk factors could be integrated into predictive models of 
mortality in individuals with SBP so as to further help 
identify patients in need of more aggressive therapeutic 
strategies from the very start of the infective process81,82. 
CONCLUSION 
SBP has a high mortality rate and early diagnosis and 
antimicrobial therapy are essential for improving patient 
outcomes. SBP is a clinical entity noted primarily in patients 
with end stage liver disease. Aerobic gram-negative bacilli 
are the predominant organisms involved. Primary 
bacteremia which occurs as a consequence of impaired 
function of the reticuloendothelial system along with an 
increase in bacterial translocation from the bowel, is 
probably followed by secondary seeding of the ascitic fluid. 
Although fever and abdominal pain are the most frequent 
clinical manifestations, the signs and symptoms may be 
subtle, or the patient may be asymptomatic. The ascitic fluid 
PMN count is the best determinant for the diagnosis of SBP; 
however, its clinical variants should be closely monitored for 
appropriate management of patients with SBP. Currently, 
cefotaxime is considered the drug of choice for treatment, 
whereas nonabsorbable antibiotics such as norfloxacin are 
used to decrease the recurrence of SBP. 
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